Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a260a6eceff7f8ab

Jump to content

// Workers AI · dad joke modeWhat did FlexGen say to its rival? You're so inflexible.

From Wikipedia, the free encyclopedia
FlexGen B.V.
IndustryBiotechnology
Founded2004
Headquarters,
Area served
Worldwide
ProductsFlexArrayer, FleXelect custom oligopools
ServicesCustom oligopool synthesis
Websitehttp://www.flexgen.nl

FlexGen was a biotechnology company based in Leiden, Netherlands. FlexGen was a spin-off from Leiden University Medical Centre and Dutch Space (part of EADS) and had proprietary technologies for laser based in-situ synthesis of oligonucleotides and other biomolecules. On 21 December 2015, Flexgen Bv in Leiden (South Holland) was declared bankrupt by the court in Gelderland Source.

Products

[edit]

FleXelect

[edit]

FleXelect oligopools Archived 2011-07-24 at the Wayback Machine consist of custom oligonucleotides in solution and can be used for in solution target enrichment prior to next generation DNA sequencing. Target enrichment or In solution hybrid selection is a method for genomic selection in an increasing number of applications[1][2] such as;

  1. Analysis of custom genomic regions of interest (e.g. specific genes, multiple variants and/or complete pathways).
  2. Analysis of Chromosomal translocation
  3. Validation of Single-nucleotide polymorphism or SNPs (typically after whole genome or whole exome studies)
  4. Other research and diagnostic applications (e.g. Synthetic biology)

An example of a recent application is testing of the BRCA1 and BRCA2 breast cancer risk genes[3]

FlexArrayer

[edit]

The FlexArrayer Archived 2011-07-24 at the Wayback Machine is an in-house custom oligonucleotide synthesis instrument. The FlexArrayer facilitates high throughput synthesis of FleXelect oligopools for in-solution target enrichment as well as custom microarray production. The FlexArrayer is also applicable for array based re-sequencing.[4]

The FlexArrayer provides microarray and oligopool synthesis typically used by:

  1. Genomics centres and sequencing facilities
  2. Health and safety institutes & microbiology labs
  3. Technology innovators in the fields of: Surface chemistries, PNA's (Peptide nucleic acid), siRNA's (Small interfering RNA) and more

Technology

[edit]

Production of microarrays and FleXelect oligopools is done with the FlexArrayer (see image) using proprietary technology. The FlexArrayer synthesizes custom probesets on a substrate based on oligonucleotide deprotection technology;

  1. Before the first oligonucleotide synthesis step the complete DNA microarray surface is covered by photolabile groups.
  2. Those spots the first nucleotide addition is to occur are individually activated by the laser .
  3. The nucleotide solution is washed over the microarray surface and the nucleotides chemically bind to the activated spots.
  4. All nucleotides contain a photolabile group that can in turn be activated. As many rounds of photoactivation and nucleotide addition are performed as are required to synthesize oligonucleotides of the desired length.
  5. This is repeated up to 60 times until the required sequences (up to 100.000) have been synthesized. Thus, the maximum length of any oligonucleotide produced on this platform is 60mer in length.
  6. The microarray is now ready to be used, alternatively the oligonucleotides can be cleaved off to produce FleXelect oligopools.
The FlexArrayer, an oligonucleotide synthesis instrument.

References

[edit]
  1. Mamanova, L.; Coffey, A. J.; Scott, C. E.; Kozarewa, I.; Turner, E. H.; Kumar, A.; Howard, E.; Shendure, J.; Turner, D. J. (2010). "Target-enrichment strategies for next-generation sequencing". Nature Methods. 7 (2): 111–118. doi:10.1038/nmeth.1419. PMID 20111037. S2CID 262690899.Mamanova, L.; Coffey, A. J.; Scott, C. E.; Kozarewa, I.; Turner, E. H.; Kumar, A.; Howard, E.; Shendure, J.; Turner, D. J. (2010). "Target-enrichment strategies for next-generation sequencing". Nature Methods. 7 (6): 479. doi:10.1038/nmeth0610-479c.
  2. Tewhey, R.; Nakano, M.; Wang, X.; Pabón-Peña, C.; Novak, B.; Giuffre, A.; Lin, E.; Happe, S.; Roberts, D. N.; Leproust, E. M.; Topol, E. J.; Harismendy, O.; Frazer, K. A. (2009). "Enrichment of sequencing targets from the human genome by solution hybridization". Genome Biology. 10 (10): R116. doi:10.1186/gb-2009-10-10-r116. PMC 2784331. PMID 19835619.
  3. Two European Labs Turn to Next-Gen Sequencing for BRCA1/2 Testing, INsequence, October 26, 2010.
  4. SM Carr et al., DNA "Re-Sequencing" with a microarray, 2008. Comp Biochem Physiol D, Genomics & Proteomics 3,1-11 (link)
[edit]